Discontinued — last reported Q1 '18
Copart Allowance for Doubtful Accounts Receivable (Current) remained flat by 0.0% to $14.92M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 10.5%, from $13.50M to $14.92M. Over 5 years (FY 2020 to FY 2025), Allowance for Doubtful Accounts Receivable (Current) shows an upward trend with a 15.2% CAGR. This is a positive signal — lower values indicate better performance for this metric.
A significant increase relative to receivables may signal deteriorating customer credit quality or economic headwinds in specific markets.
This is a contra-asset account representing the estimated amount of accounts receivable that the company expects will no...
Standard across all industries; peers in the medical device sector typically maintain low levels unless operating in high-risk emerging markets.
allowance_for_doubtful_accounts_receivable_current| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $5.32M | $5.64M | $5.66M | $7.04M | $6.71M | $6.58M | $7.76M | $8.60M | $8.12M | $8.64M | $9.59M | $13.64M | $12.33M | $12.53M | $13.63M | $13.50M | $12.75M | $12.95M | $14.92M | $14.92M |
| QoQ Change | — | +5.9% | +0.5% | +24.2% | -4.6% | -2.0% | +18.0% | +10.8% | -5.6% | +6.4% | +11.0% | +42.3% | -9.6% | +1.6% | +8.7% | -1.0% | -5.5% | +1.5% | +15.2% | +0.0% |
| YoY Change | — | — | — | — | +26.1% | +16.7% | +37.1% | +22.2% | +21.0% | +31.4% | +23.5% | +58.7% | +51.9% | +45.1% | +42.1% | -1.1% | +3.4% | +3.3% | +9.5% | +10.5% |